by Juveriya Israr  and Ajay Kumar

Received: 03 August 2024;  Published: 24 February 2025;  doi: 10.21926/obm.transplant.2501236

COVID-19 has presented considerable health hazards, particularly for immunocompromised persons, such as kidney transplant recipients. This population experiences increased susceptibility due to the immunosuppressive treatments necessary to avert organ rejection, potentially resulting in a diminished immune response to immunizations. The implementation of COVID-19 vaccinations has been essential in alleviating these dangers. Studies demonstrate differing levels of vaccine efficacy among kidney transplant recipients, [...]

by Jade M Kozuch  , Kamyar Afshar  and Ashley Feist

Received: 15 November 2024;  Published: 20 February 2025;  doi: 10.21926/obm.transplant.2501235

Lung transplant recipients represent a high-risk group for cytomegalovirus (CMV) infection and disease, even among solid organ transplant (SOT) recipients, due to multiple factors. Additionally, CMV has significant consequences in this group including pneumonitis, acute rejection, and chronic lung allograft dysfunction. For the past two plus decades, treatment of CMV in SOT recipients has been limited to off-label use of 4 antiviral medications associated with significant toxicities including myelosuppression and n [...]

by Rolf Teschke  and Axel Eickhoff

Received: 08 January 2025;  Published: 14 February 2025;  doi: 10.21926/obm.transplant.2501234

Liver transplantation (LT) can be the only option for patients with acute liver failure (ALF) where medical approaches are ineffective. Causes of ALF are multiple and commonly easily detectable, but uncertainty remained on the role of drug-induced liver injury (DILI) within the published ALF cohorts. Therefore, an analysis was undertaken to clarify which drugs may have caused the DILI and how the diagnosis of the liver injury was established. Using the PubMed database and Google Science, the search term of acute li [...]

by Lúcia Bacalhau  and Patrícia Pontífice-Sousa

Received: 19 September 2024;  Published: 06 February 2025;  doi: 10.21926/obm.transplant.2501233

Allogeneic Stem Cells Transplantation (ASCT) and, consequently, the chronicity associated with this life event has a growing prevalence and a significant impact on the life and daily life of each person who experiences it. The growing number of ASCT survivors highlights the need to reflect on the unique challenges they face throughout their recovery. To understand the meaning of the encounter with time in the lived experience of comfort for survivors of ASCT. Qualitative approach using van Manen's phenomenology of [...]

by Marcus Taylor  , Zakariya Mouyer  , Eltigani Abdelaal  and Nnamdi Nwaejike

Received: 23 July 2024;  Published: 22 January 2025;  doi: 10.21926/obm.transplant.2501232

The axillary intra-aortic balloon pump (ax-IABP) has been proposed as an alternative to the femoral IABP, particularly for patients with comorbidities rendering them unsuitable for fem-IABP insertion. Patient mobilisation with the ax-IABP in situ is deemed an additional potential benefit. We reviewed our experience with the ax-IABP. A single-centre retrospective review of all adult patients undergoing cardiac surgery (including heart transplantation) in a UK quaternary cardiac surgery centre between 2017 and 2021 w [...]

by Ziyad Alharbi

Received: 27 March 2024;  Published: 13 January 2025;  doi: 10.21926/obm.transplant.2501231

The supraclavicular artery flap presents a promising solution for facial reconstruction challenges since 1997, surpassing limitations of traditional methods like the deltopectoral flap. Its extended pedicle and thin, pliable epidermis offer reliable outcomes with minimal donor site morbidity, making it a preferred choice for head and neck reconstruction. This systematic review evaluates the efficacy of pre-expanded supraclavicular artery flaps based on a comprehensive analysis. In accordance with the Preferred Repo [...]

by A. Isabella Shanker  , Lauren T. Maloney  and Julia M. Boster

Received: 23 September 2024;  Published: 10 January 2025;  doi: 10.21926/obm.transplant.2501230

Infection is a leading cause of short-term morbidity and mortality in pediatric patients after liver transplant (LT). Diagnosing infection in this population can be challenging, requiring consideration of laboratory results and clinical context. The prevalence and significance of post-operative leukocytosis has not yet been explored in children after LT. Our goals were to characterize post-transplant leukocytosis in pediatric patients after LT for biliary atresia (BA) and evaluate the relationship between post-LT l [...]

by OBM Transplantation Editorial Office

Received: 02 January 2025;  Published: 02 January 2025;  doi: 10.21926/obm.transplant.2501229

The editors of OBM Transplantation would like to express their sincere gratitude to the following reviewers for assessing manuscripts in 2024. We greatly appreciate the contribution of expert reviewers, which is crucial to the journal’s editorial process. We aim to recognize reviewer contributions through several mechanisms, of which the annual publication of reviewer names is one. Reviewers can download a certificate of recognition directly from our submission system. Additionally, reviewers can sign up to t [...]

by Mouna Daldoul  , Rim Charfi  , Khouloud Ferchichi  , Mouna Ben Sassi  , Syrine Ben Hammamia  , Fatma Medhioub  , Emna Gaies  , Rym Enneifer  , Hanene Eljebari  , Anis Klouz  , Riadh Daghfous  and Sameh Trabelsi

Received: 20 August 2024;  Published: 13 December 2024;  doi: 10.21926/obm.transplant.2404228

A high intra and interindividual pharmacokinetics variability characterize Tacrolimus. Data regarding factors influencing its pharmacokinetics and pharmacodynamics in liver transplantation are limited. This study aimed to assess tacrolimus therapeutic response, pharmacokinetics and adherence in liver transplant recipients. The study was conducted at the Clinical Pharmacology Department for 12 years, from January 2009 to March 2021. We included liver transplant patients treated with tacrolimus referred to our depart [...]

by Michael Y. Shino  , Francisco Javier Ibarrondo  , Jesse L. Clark  , Adreanne Rivera  , Marlene Florian  , Allison Ramsey  , Ariss Derhovanessian  , Rajan Saggar  , Olawale O. Amubieya  , Grant Turner  , Joanna M. Schaenman  , Pryce T. Gaynor  , Omer E. Beaird  , Ashrit Multani  , Reshma M. Biniwale  , Murray H. Kwon  , Christos J. Petropoulos  , Yolanda Lie  , Terri Wrin  , Amparo L. Figueroa  , Brett Leav  , Zelalem Endale  , Kate Anteyi  , Jacqueline M. Miller  , Abbas Ardehali  , David M. Sayah  , David Elashoff  , John A. Belperio  , Otto O. Yang  and S. Sam Weigt

Received: 16 August 2024;  Published: 20 November 2024;  doi: 10.21926/obm.transplant.2404227

Higher-dose mRNA booster vaccines have not been well studied for transplant recipients. This study evaluated the safety, reactogenicity and immunogenicity of higher dose mRNA-1273 booster vaccines among lung transplant recipients (LTRs). This phase 1/2 open-label randomized clinical trial of higher-dose mRNA-1273 booster vaccination enrolled nineteen adult LTRs into the 50 µg (n = 8) vs. 100 µg (n = 11) groups before enrollment was terminated due to the availability of the bivalent mRNA-1273.222 vaccine [...]